Literature DB >> 9702949

International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators.

J R Tate1, N Rifai, K Berg, R Couderc, F Dati, G M Kostner, I Sakurabayashi, A Steinmetz.   

Abstract

A secondary reference material for lipoprotein(a) is required to standardize the measurement of lipoprotein(a) in clinical laboratories worldwide. Towards this aim, the International Federation of Clinical Chemistry Working Group for the Standardization of Lipoprotein(a) Assays has initiated a standardization project involving a total of 33 diagnostic company and clinical chemistry laboratories from 12 countries. In Phase 1, the analytical performance of 40 lipoprotein(a) assay systems was evaluated by testing sera and manufactured lipoprotein(a) calibrator materials for precision, linearity, and parallelism. Twenty test systems were nonoptimized according to the results for a pooled serum, which tested nonlinear in 16 systems and imprecise in 4. Acceptable analytical properties and harmonization of lipoprotein(a) values were shown by some commercial calibrators, suggesting their possible use as reference materials. This study highlights the problems that currently occur for lipoprotein(a) measurement in existing assay systems.

Mesh:

Substances:

Year:  1998        PMID: 9702949

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  13 in total

1.  Reference materials and commutability.

Authors:  Hubert W Vesper; W Gregory Miller; Gary L Myers
Journal:  Clin Biochem Rev       Date:  2007-11

Review 2.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

3.  Evaluation of a new apolipoprotein(a) isoform-independent assay for serum Lipoprotein(a).

Authors:  T Dembinski; P Nixon; G Shen; D Mymin; P C Choy
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

4.  Association between different growth curve definitions of overweight and obesity and cardiometabolic risk in children.

Authors:  Lisa Kakinami; Mélanie Henderson; Edgard E Delvin; Emile Levy; Jennifer O'Loughlin; Marie Lambert; Gilles Paradis
Journal:  CMAJ       Date:  2012-04-30       Impact factor: 8.262

5.  Which one of LDL-C /HDL-C ratio and non-HDL-C can better predict the severity of coronary artery disease in STEMI patients.

Authors:  Po Gao; Xiang Wen; Qiaoyun Ou; Jing Zhang
Journal:  BMC Cardiovasc Disord       Date:  2022-07-17       Impact factor: 2.174

6.  Comparison of different severe obesity definitions in predicting future cardiometabolic risk in a longitudinal cohort of children.

Authors:  Lisa Kakinami; Anna Smyrnova; Gilles Paradis; Angelo Tremblay; Melanie Henderson
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

Review 7.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

8.  Current perspectives on laboratory markers for the assessment of cardiovascular disease and myocardial damage.

Authors:  S Narayanan
Journal:  Indian J Clin Biochem       Date:  1999-07

9.  Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.

Authors:  Deepti Gurdasani; Barbara Sjouke; Sotirios Tsimikas; G Kees Hovingh; Robert N Luben; Nicholas W J Wainwright; Cristina Pomilla; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

10.  Exercise-referral scheme to promote physical activity among hypertensive patients: design of a cluster randomized trial in the Primary Health Care Units of Mexico's Social Security System.

Authors:  Katia Gallegos-Carrillo; Carmen García-Peña; Jorge Salmerón; Velia Nelly Salgado-de-Snyder; Gabriel Vázquez-Cabrer; Felipe Lobelo
Journal:  BMC Public Health       Date:  2014-07-09       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.